Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2026-05-06 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
关于使用闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the progress of using idle self-owned funds to purchase financial products. It details the authorization, amounts, counterparties, and risk controls related to the company's cash management and investment in bank wealth management products. The document is relatively short (3077 characters) and focuses on disclosing a specific financing activity involving the company's own funds, not a full financial report or earnings release. It does not contain comprehensive financial statements or management discussion and analysis. It is an update on capital usage and financing activities, specifically about the company's cash management and investment in financial products. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-05-06 Chinese
关于参加浙江辖区上市公司2026年投资者网上集体接待日暨2025年度业绩说明会预告公告
AGM Information Classification · 90% confidence The document is a public announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. about their participation in an upcoming investor online collective reception day and the 2025 annual performance explanation meeting. It references the 2025 Annual Report (disclosed earlier) but does not contain the report itself or detailed financial data. The document mainly serves as a notice for an investor meeting and invites investors to submit questions. The document length is short (946 characters), and it is clearly an announcement about an event related to the annual report, not the report itself. Therefore, it fits the category of an Investor Presentation announcement or meeting notice. However, since it is not the presentation itself but a notice about the meeting, the best fitting category is AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or related investor meetings. Confidence is high due to clear event details and reference to the annual report without containing the report itself.
2026-05-06 Chinese
董事会关于独立董事独立性自查情况专项报告
Board/Management Information Classification · 95% confidence The document is a special report from the board of directors regarding the independence of the company's independent directors. It details the self-assessment and evaluation of the independent directors' independence according to regulatory requirements. The content focuses on governance and compliance with independence criteria, rather than financial results, audit opinions, or shareholder voting outcomes. It is not an annual report, audit report, earnings release, or any financial statement. It is also not a notice of voting results or a proxy solicitation. The document fits best under Board/Management Information (MANG) as it relates to board-level governance and director information, specifically about the independence of independent directors.
2026-04-15 Chinese
2026年董事、高级管理人员薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the 2026 remuneration scheme for the company's directors and senior management. It details the salary structure, payment terms, and approval process for the remuneration plan. There is no financial data, audit information, or report content. It is not a full report but a disclosure about management compensation policies. This fits the definition of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors.
2026-04-15 Chinese
关于董事会审计委员会2025年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee of Zhejiang Haisheng Pharmaceutical Co., Ltd. detailing their activities and performance during the 2025 fiscal year. It includes information about meetings held, audit reviews, evaluations of external auditors, and overall assessment of the committee's work. The document is not an announcement of a report publication but the actual report on the audit committee's duties and findings. It does not contain full financial statements but focuses on audit committee activities and oversight. This fits the category of Audit Report / Information (AR), which covers standalone audit reports and related information excluding full annual reports. The document length is 3225 characters, which is sufficient for a detailed committee report but not a full annual report. Therefore, the classification is AR with high confidence. FY 2025
2026-04-15 Chinese
长江证券承销保荐有限公司关于浙江海昇药业股份有限公司使用部分闲置募集资金进行现金管理的专项核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from the underwriting and sponsorship institution regarding the use of idle raised funds by Zhejiang Haisheng Pharmaceutical Co., Ltd. It includes specifics about the fundraising amount, usage progress, storage of funds, reasons for idle funds, investment products for cash management, decision-making process, risk control measures, and the impact on the company. The document references regulatory approvals and compliance with Beijing Stock Exchange rules. It is not a brief announcement but a substantive report on the use of raised funds and cash management activities. This fits the category of Capital/Financing Update (CAP), as it provides updates on the company's fundraising and capital usage activities, including cash management of idle raised funds.
2026-04-15 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.